Alzamend Neuro, Inc.ALZNNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank5
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P5
Near historical low
vs 5Y Ago
-1.7x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -89.87% |
| Q3 2025 | 286.72% |
| Q2 2025 | 0.68% |
| Q1 2025 | 43.72% |
| Q4 2024 | 50.60% |
| Q3 2024 | 12.62% |
| Q2 2024 | -90.39% |
| Q1 2024 | -4.41% |
| Q4 2023 | -15.60% |
| Q3 2023 | 43.56% |
| Q2 2023 | -42.95% |
| Q1 2023 | 88.46% |
| Q4 2022 | 11.41% |
| Q3 2022 | -17.17% |
| Q2 2022 | 90.14% |
| Q1 2022 | -50.08% |
| Q4 2021 | 90.96% |
| Q3 2021 | 213.09% |
| Q2 2021 | 24.94% |
| Q1 2021 | -50.67% |
| Q4 2020 | 53.77% |
| Q3 2020 | 27.21% |
| Q2 2020 | -43.11% |
| Q1 2020 | 113.41% |
| Q4 2019 | 0.00% |
| Q3 2019 | -57.56% |
| Q2 2019 | 0.00% |
| Q1 2019 | -65.83% |
| Q4 2018 | 0.00% |
| Q3 2018 | 780.84% |
| Q2 2018 | 0.00% |
| Q1 2018 | 2941.67% |
| Q4 2017 | 0.00% |
| Q3 2017 | -96.26% |
| Q2 2017 | 0.00% |
| Q1 2017 | 0.00% |
| Q4 2016 | 0.00% |
| Q3 2016 | 0.00% |